Progress in research of sensitive markers to neoadjuvant chemotherapy in muscle invasive bladder cancer / 中华泌尿外科杂志

ABSTRACT

Bladder cancer is one of the tenth most common malignant tumors in Chinese men.Almost 20％ to 30％ patients are diagnosed as the muscle-invasive bladder cancer (MIBC) at the first diagnosis.In the past,radical cystectomy (RC) was the first-line treatment with MIBC.The current researches'results show that,neoadjuvant chemotherapy combined with RC can improve the tumor complete response rate and prolong the overall survival of patients with MIBC,comparing with the RC alone.It has become the recommended standard first line treatment for MIBC,which has the possiblity of preserving bladder.Lots of researches indicate that the application of cisplatin-based neoadjuvant chemotherapy in patients with MIBC is becoming more and more popular.However,there is still the possibility of ineffectiveness or tumor progression.Therefore,discussions about the sensitivity of neoadjuvant chemotherapy have always been a hot spot in urological tumor research.In order to provide guidance and help for clinical work,the article reviews the sensitivity of neoadjuvant chemotherapy of bladder urothelial carcinoma.